Outset Medical, Inc. Files DEF 14A with Executive Compensation Details

Ticker: OM · Form: DEF 14A · Filed: Apr 11, 2024 · CIK: 1484612

Outset Medical, INC. DEF 14A Filing Summary
FieldDetail
CompanyOutset Medical, INC. (OM)
Form TypeDEF 14A
Filed DateApr 11, 2024
Risk Level
Pages16
Reading Time19 min
Sentimentneutral

Sentiment: neutral

Topics: DEF 14A, Outset Medical, Executive Compensation, Stock Awards, Option Awards

TL;DR

<b>Outset Medical, Inc. filed a DEF 14A detailing executive compensation adjustments for stock and option awards across multiple fiscal years.</b>

AI Summary

Outset Medical, Inc. (OM) filed a Proxy Statement (DEF 14A) with the SEC on April 11, 2024. The filing is a DEF 14A from Outset Medical, Inc., dated April 11, 2024. It details adjustments to compensation fair value for outstanding and unvested option awards and stock awards granted in fiscal years 2020, 2021, 2022, and 2023. Specific adjustments are noted for both PEO and Non-PEO members. The filing includes information on the fair value of awards at fiscal year-end and at vesting dates. It also covers changes in fair value for awards granted in prior fiscal years that met or failed to meet vesting conditions.

Why It Matters

For investors and stakeholders tracking Outset Medical, Inc., this filing contains several important signals. This filing provides transparency into how executive compensation, specifically through stock and option awards, is valued and adjusted based on vesting conditions and fiscal year-end assessments. Understanding these adjustments is crucial for investors to accurately assess the total compensation of key executives and its potential impact on shareholder value.

Risk Assessment

Risk Level: — Outset Medical, Inc. shows moderate risk based on this filing. The filing is a routine DEF 14A and does not contain new financial performance data or significant strategic changes, making the immediate risk low.

Analyst Insight

Review the specific fair value adjustments for PEO and Non-PEO members to understand the impact on executive compensation and potential dilution.

Key Numbers

Key Players & Entities

FAQ

When did Outset Medical, Inc. file this DEF 14A?

Outset Medical, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 11, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Outset Medical, Inc. (OM).

Where can I read the original DEF 14A filing from Outset Medical, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Outset Medical, Inc..

What are the key takeaways from Outset Medical, Inc.'s DEF 14A?

Outset Medical, Inc. filed this DEF 14A on April 11, 2024. Key takeaways: The filing is a DEF 14A from Outset Medical, Inc., dated April 11, 2024.. It details adjustments to compensation fair value for outstanding and unvested option awards and stock awards granted in fiscal years 2020, 2021, 2022, and 2023.. Specific adjustments are noted for both PEO and Non-PEO members..

Is Outset Medical, Inc. a risky investment based on this filing?

Based on this DEF 14A, Outset Medical, Inc. presents a moderate-risk profile. The filing is a routine DEF 14A and does not contain new financial performance data or significant strategic changes, making the immediate risk low.

What should investors do after reading Outset Medical, Inc.'s DEF 14A?

Review the specific fair value adjustments for PEO and Non-PEO members to understand the impact on executive compensation and potential dilution. The overall sentiment from this filing is neutral.

How does Outset Medical, Inc. compare to its industry peers?

The filing pertains to the healthcare sector, specifically the electromedical and electrotherapeutic apparatus industry.

Are there regulatory concerns for Outset Medical, Inc.?

The filing is made under the Securities Exchange Act of 1934, requiring public companies to disclose information about executive compensation.

Industry Context

The filing pertains to the healthcare sector, specifically the electromedical and electrotherapeutic apparatus industry.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring public companies to disclose information about executive compensation.

What Investors Should Do

  1. Analyze the specific dollar amounts associated with fair value adjustments for PEO and Non-PEO members.
  2. Compare the fair value changes of stock and option awards across different fiscal years.
  3. Investigate the reasons behind awards failing to meet vesting conditions, if detailed.

Key Dates

Year-Over-Year Comparison

This is a DEF 14A filing, which typically provides updated information on executive compensation and corporate governance, rather than a direct comparison to a previous financial filing.

Filing Stats: 4,718 words · 19 min read · ~16 pages · Grade level 12.5 · Accepted 2024-04-11 16:05:31

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 28 Board and Corporate Governance Matters 8 Proposal Two: Advisory Vote on Named Executive Officer Compensation 28 Proposal One: Election of Directors 8 Compensation Discussion and Analysis 29 Overview of Our Nominees and Continuing Directors 9 Compensation Committee Report 45 2023 Summary Compensation Table 46 Board Structure and Composition 16 Grants of Plan-Based Awards in 2023 48 Director Independence 16 Outstanding Equity Awards at 2023 Year-End 50 Board Leadership Structure 16 Option Exercises and Stock Vested in 2023 51 Role of our Board in Risk Oversight 17 Additional Narrative Disclosure 52 Meetings of our Board 19 Compensation Risk Assessment 54 Committees of our Board 19 CEO Pay Ratio 54 Committee Composition and Meetings 19 Pay Versus Performance 55 Audit Committee 19 Equity Plan Information 61 Compensation Committee 20 Equity Compensation Plan Information 61 Compensation Committee Interlocks and Insider Participation 21 Stock Ownership 62 Nominating and Corporate Governance Committee 21

Security Ownership of Certain Beneficial

Security Ownership of Certain Beneficial 62 Director Nomination Process 22 Delinquent Section 16(a) Reports 64 Stockholder Engagement 23 Audit Matters 65 Code of Ethics and Business Conduct 23 Proposal Three: Ratification of Appointment of Independent Registered Public Accounting Firm 65 Corporate Governance Guidelines 24 Stock Ownership Guidelines 24 Report of the Audit Committee 66 Recoupment Policy 24 Additional Information 67 Anti-Hedging and Anti-Pledging Policy 25 Other Matters 67 Stockholder Communications with our Board 25 Stockholder Proposals and Nominations for Next Year's Annual Meeting of Stockholders 67 Certain Relationships and Related Party Transactions 25 Availability of Annual Report on Form 10-K 67 Director Compensation 26 APPENDIX A – NON-GAAP RECONCILIATIONS A- 1 Non-Employee Director Compensation Policy 26 2023 Director Compensation Table 27 Table of Contents Proxy Statement For the 2024 Annual Meeting of Stockholders To be held on May 29, 2024 Annual Meeti ng Information Our Board of Directors ("Board") is soliciting your proxy for the 2024 Annual Meeting of Stockholders (the "Annual Meeting") of Outset Medical, Inc. ("Outset," the "Company," "we," "us" or "our") and at any adjournment, continuation or postponement of the meeting for the purposes described in this proxy statement and the accompanying Notice of 2024 Annual Meeting of Stockholders. The Annual Meeting will take place on May 29, 2024 at 1:30 p.m. Pacific Time in a virtual format via live audio webcast. If you held shares of our common stock as of the close of business on the record date, April 2, 2024, you are invited to attend the meeting at www.virtualshareholdermeeting.com/OM2024 and vote on the proposals described in this proxy statement. On or about April 11, 2024, we will be mailing a Notice of Internet Availability of Proxy Materials (the "Internet Notice"

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing